J2KBIO's earnings have been declining at an average annual rate of -3%, while the Biotechs industry saw earnings growing at 15.2% annually. Revenues have been growing at an average rate of 14.9% per year. J2KBIO's return on equity is 11.9%, and it has net margins of 10.9%.
How J2KBIO makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
KOSDAQ:A420570 Revenue, expenses and earnings (KRW Millions)
Date
Revenue
Earnings
G+A Expenses
R&D Expenses
31 Mar 26
36,824
4,029
6,705
2,570
31 Dec 25
32,966
2,673
6,745
2,427
30 Sep 25
31,125
2,249
6,551
2,163
30 Jun 25
29,074
1,161
6,879
2,131
31 Mar 25
32,588
2,890
6,418
1,950
31 Dec 24
33,129
-1,653
6,419
1,902
30 Sep 24
34,706
-656
5,985
1,786
30 Jun 24
35,922
1,009
5,429
1,537
31 Mar 24
30,848
-312
5,199
1,402
31 Dec 23
28,472
4,844
4,332
1,217
30 Sep 23
24,473
4,165
4,049
1,047
30 Jun 23
21,088
3,356
3,668
1,019
31 Mar 23
17,791
2,501
3,536
945
31 Dec 22
16,032
2,086
3,562
878
31 Dec 21
14,219
1,623
3,012
778
31 Dec 20
13,858
1,475
2,599
761
Quality Earnings: A420570 has high quality earnings.
Growing Profit Margin: A420570's current net profit margins (10.9%) are higher than last year (8.9%).
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: A420570's earnings have declined by 3% per year over the past 5 years.
Accelerating Growth: A420570's earnings growth over the past year (39.4%) exceeds its 5-year average (-3% per year).
Earnings vs Industry: A420570 earnings growth over the past year (39.4%) exceeded the Biotechs industry 22.6%.
Return on Equity
High ROE: A420570's Return on Equity (11.9%) is considered low.
Return on Assets
Return on Capital Employed
Discover strong past performing companies
7D
1Y
7D
1Y
7D
1Y
Company Analysis and Financial Data Status
Data
Last Updated (UTC time)
Company Analysis
2026/07/01 02:57
End of Day Share Price
2026/07/01 00:00
Earnings
2026/03/31
Annual Earnings
2025/12/31
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
J2KBIO Co., Ltd. is covered by 0 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.